With ProFound, Flagship explores ‘dark proteome’ at the ribosome
The Cambridge-based company emerged from stealth with $75 million
Flagship-built ProFound Therapeutics is exploring tens of thousands of proteins others have missed, with the goal of discovering new targets and therapeutics.
Founded in 2020, ProFound Therapeutics Inc. emerged from stealth Thursday with $75 million from Flagship Pioneering to focus on proteins ignored by traditional technologies and categorization rules. “It’s mostly a human construct that the ‘dark proteome’ existed,” said ProFound CEO and cofounder Avak Kahvejian, who is also a general partner at Flagship...